How should you talk to friends about rejection? Can Facebook actually improve the lives of children? And how’s biotech doing in China?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we talk about the FDA’s surprise decision to reject a drug from Sarepta Therapeutics — and the company’s curious way of explaining it. Then, STAT’s Shraddha Chakradhar joins us to talk about the growing online community devoted to helping toddlers get access to Zolgensma, Novartis’ $2.1 million rare disease treatment. Finally, biotech investor Brad Loncar dials in to explain how the Chinese biotech sector has evolved and where it’s headed.
For more on what we cover, here’s the Sarepta news; here’s the story on Zolgensma advocacy; and here’s more on Novartis’s situation.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].
